Group 1: Zhijiang Biology - The company plans to invest approximately 60 million yuan in R&D for 2024, with expected growth in 2025 [1] - The focus is on innovation in molecular diagnostic technology, particularly in early cancer screening, companion diagnostics, and precision treatment [1] - Collaboration with Sanyou Biology includes four ongoing projects, with one entering the patent application stage [1] - The company aims to provide customized models and one-stop solutions through organoid services targeting research and medical institutions [1] - Future investments in Sanyou Biology will consider strategic layout, shareholder interests, and market conditions [1] - The company has completed three rounds of share purchases and is conducting a second purchase for 2025, with future plans dependent on circumstances [1] - The development strategy emphasizes technological innovation, product line expansion, and international market exploration [1] - Overseas plans include enhancing global presence, establishing smart manufacturing facilities, and improving localized team management [1] Group 2: Pengding Holdings - The company is focusing on the development of AI server capabilities, with production capacity established in Huai'an, mainland China, and Thailand [2] - Investment and expansion plans will be adjusted based on market demand and strategic considerations [2] - The first phase of the Thailand project is completed, currently undergoing customer certification and sampling, with small-scale production expected in the second half of the year [2] - Cost assessments for the Thailand facility will be conducted post-mass production, with plans to optimize production processes and supply chain management for cost efficiency [2] - Capital expenditure will primarily target the Thailand facility, soft board expansion, and advanced HDI and SLP projects in Huai'an [2] - The company is cautious about commenting on new product requirements due to the upcoming product launch, which may affect production processes and performance [2] - The timeline from equipment setup to production is approximately six months, contingent on facility and mechanical conditions [2]

Core Viewpoint - Amway Co., Ltd. has officially become a supplier for New Balance, marking a significant milestone in its international recognition and market expansion efforts [1] Group 1: Partnership Details - The partnership with New Balance will commence in 2024, following extensive evaluations including raw material quality control, laboratory development, and production capacity [1] - New Balance conducted an on-site inspection of Amway in March 2025 and completed the supplier audit by June 2025 [1] Group 2: Product Offering - Amway will primarily supply eco-friendly functional polyurethane synthetic leather and composite materials for New Balance footwear [1] Group 3: Strategic Implications - This collaboration highlights Amway's technological and comprehensive management capabilities, enhancing its brand image and facilitating entry into international markets [1]

Core Viewpoint - The company responded to the regulatory inquiry regarding its 2024 annual report, addressing questions about customer and supplier relationships, sales contracts, and the impact of its actual controller's agreements on business stability [1][2][3]. Customer and Supplier Relationships - The top five customers contributed sales of 226.87 million yuan, accounting for 41.53% of total annual sales, with significant sales to related parties [1][2]. - The company reported a total procurement of 68.22 million yuan from its top five suppliers, representing 18.73% of total annual procurement, with two suppliers changing during the year [1][2]. Sales Contracts and Performance - The company detailed the performance of new major customers, including the completion of product deliveries and revenue recognition for various projects, with a total of 29.11 million yuan recognized from major projects [2][3]. - The company highlighted that the revenue from the new major customer, Dadi Engineering Development Group, was primarily due to the Wanfu TDS project, which faced delays due to operational issues at the end-user site [2][3]. Impact of Agreements on Control and Stability - The company’s actual controller signed a concerted action agreement with Dadi Company, which is set to expire on December 9, 2025, with no immediate plans for renewal [4][5]. - The agreement has historically increased the controller's voting power from 51.30% to 70.47%, but is expected to stabilize at 38.47% post-expiration, which does not significantly affect control [5][6]. Business Cooperation and Market Position - The business model with Dadi Company is based on a contractor-supplier relationship, with the company maintaining an independent sales system and the ability to secure orders without reliance on Dadi [6][8]. - The company has established a strong cooperative relationship with Dadi, which has resulted in a stable revenue stream, with a decreasing proportion of sales to related parties over the years [10][11]. Revenue Recognition and Sales Policies - The company maintains consistent revenue recognition policies for both related and non-related parties, ensuring that sales are recognized upon delivery and acceptance by the end customer [15][19]. - The pricing for sales to related parties is based on market conditions and cost-plus models, with no significant anomalies detected in pricing practices [12][14]. Financial Performance and Projections - As of April 30, 2025, the company reported cumulative sales to related parties amounting to 84.45 million yuan, with a collection rate of 53.10% [19]. - The company anticipates continued stability in its revenue streams and customer relationships, regardless of the expiration of the concerted action agreement [9][10].